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E-mail address: maikeda@md.okayama-u.ac.jp (MOncostatin M (OSM), a member of the interleukin-6 family, possesses various functions, including
hepatocyte differentiation and suppression of melanoma cell growth. Here, we report anti-hepatitis
C virus (HCV) activity of OSM as a new function of this cytokine. OSM possessed marked anti-HCV
activity (50% effective concentration: 0.71 ng/ml) in an HCV RNA replication cell culture system.
The most striking ﬁnding is that OSM exhibited synergistic inhibitory activity on interferon (IFN)-
a even at a low concentration with weak anti-HCV activity, such as 25 pg/ml. OSM is a candidate
anti-HCV reagent and may improve the current IFN therapy for patients with chronic hepatitis C.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Currently the combination therapy of pegylated-interferon-a
(PEG-IFN-a) with ribavirin (RBV) is available for patients with
chronic hepatitis C (CH C). However, the sustained virological re-
sponse (SVR) rate is still approximately 55% [1]. There is thus an
urgent need for novel partners for IFN.
Oncostatin M (OSM) belongs to the interleukin (IL)-6 family,
which also includes IL-6, IL-11, IL-27, ciliary neurotrophic factor,
cardiotrophin-like cytokine, cardiotrophin-1, neuropoietin and
leukemia-inhibitory factor (LIF) [2,3]. OSM was ﬁrst reported as a
cytokine produced from U-937 lymphoma cells, when it was found
to inhibit the growth of melanoma cells [4]. The IL-6 family mem-
bers share glycoprotein 130 (gp130) for signal transduction, and
the OSM receptor consists of gp130 and its unique OSMR [5].
Recently it was reported that the IL-31 receptor also contains
OSMR and forms a heterodimer with IL31RA [6]. OSMR and
gp130 are highly expressed in liver, and OSM plays a signiﬁcant
role in the differentiation and regeneration of liver [7,8]. Therefore,chemical Societies. Published by E
e; CH C, chronic hepatitis C;
lomyocarditis virus; gp130,
N, pegylated-interferon; IL,
, leukemia-inhibitory factor;
in; RL, Renilla luciferase; RT-
; STAT, signal transducer and
. Ikeda).OSM was used as a reagent for the differentiation of hepatocytes
in vitro.
Here, we have found that OSM’s anti-hepatitis C virus (HCV)
activity is a new function of this cytokine. OSM synergistically
inhibited HCV RNA replication in combination with IFN-a even at
a low concentration with weak anti-HCV activity (20% inhibition).
OSM may improve the current PEG-IFN-a and RBV therapy for pa-
tients with CH C and provide a clue toward understanding the di-
verse sensitivity to IFN therapy.2. Materials and methods
2.1. Compounds and antibodies
IFN-awas purchased from Sigma (St. Louis, MO). OSM and IL-31
were purchased from R&D Systems (Minneapolis, MN). IL-6 was
purchased from Acris Antibodies (Herford, Germany). LIF was pur-
chased from Chemicon International (Temecula, CA). Anti-HCV
core antibody (CP11) was purchased from the Institute of Immu-
nology (Tokyo, Japan), and anti-HCV non-structural 5A (NS5A)
antibody was the generous gift of Dr. A. Takamizawa (Research
Foundation for Microbial Diseases, Osaka University). Anti-b-actin
antibody was purchased from Sigma. Anti-signal transducer and
activator of transcription (STAT) 1 and anti-STAT3 antibodies were
purchased from BD Bioscience (San Jose, CA). Anti-phospho-STAT1
(Y701) and anti-phospho-STAT3 (Y705) were purchased from Cell
Signaling Technology (Danvers, MA).lsevier B.V. All rights reserved.
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The OR6 cell line is cloned from ORN/C-5B/KE (strain O of geno-
type 1b) RNA replicating HuH-7 cells, as described previously [9].
OR6c cells are cured OR6 cells from which HCV RNA was
eliminated by IFN-a treatment, as previously described [10].
HCV-O/RLGE (strain O) is the authentic HCV RNA containing adap-
tive mutations of Q1112R, P1115L, E1202G, and K1609E in the NS3
region and replicates efﬁciently in OR6c cells [11]. Li23 and PH5CH
cells were cultured as previously described [12].
2.3. OR6 reporter assay
For the Renilla luciferase (RL) assay, 1.5  104 OR6 cells were
plated onto 24-well plates in triplicate and pre-cultured for 24 h.
The cells were treated with OSM and/or IFN-a for 72 h. After the
treatment, the cells were harvested with Renilla lysis reagent (Pro-
mega, Madison, WI) and subjected to RL assay according to the
manufacturer’s protocol.
2.4. Cell growth assay
To examine OSM’s activity in OR6 cell growth, 6.0  104 OR6
cells were plated onto 6-well plates in triplicate and were pre-cul-
tured for 24 h. The cells were treated with OSM for 72 h, and then
the number of viable cells was counted after trypan blue dye treat-
ment, as previously described [13].
2.5. Reverse transcription and polymerase chain reaction (RT-PCR)
RT-PCR for gp130, OSMR, LIFR, IL6R, IL31RA and glyceraldehyde-
3-phosphate dehydrogenase was performed by a method described
previously [14]. Brieﬂy, using cellular total RNAs (2 lg), cDNA was
synthesized using M-MLV reverse transcriptase with oligo dT pri-Fig. 1. Anti-HCV activity of OSM in HCV RNA replicating OR6 cells. (A) Schematic gene org
adaptive mutation, K1609E, is indicated by a black triangle. (B) OR6 cells were treated
calculated when the RL activity of the control was assigned as 100%. (C) OR6 cells were
staining. (D) OR6 cells were treated with OSM and harvested at 24, 48, 72, and 96 h andmer. One-tenth of the synthesized cDNA was subjected to PCR with
the speciﬁc primer pairs (Supplementary materials).
2.6. Western blot analysis
For Western blot analysis to detect the expression of core and
NS5A, 4  104 OR6c cells harboring HCV-O/RLGE RNA were plated
onto 6-well plates and cultured for 24 h, and then were treated
with IFN-a and/or OSM for 72 h. To detect the STATs and phos-
phorylated STATs, 5  105 OR6 cells were plated onto 6-well plates
and cultured for 24 h, and then were treated with IFN-a and/or
OSM. Preparation of the cell lysates, sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis and immunoblotting were then
performed as previously described [15].
3. Results
3.1. OSM inhibited HCV RNA replication in hepatoma cell line
We have tried to develop differentiated hepatocytes from
mesenchymal stem cells using OSM as the differentiation reagent
to establish the cell culture system for HCV RNA replication. We
tested the reagents needed for differentiation, including OSM, to
rule out negative activity for HCV RNA replication. In the course
of this procedure, we happened to ﬁnd that OSM possessed
marked anti-HCV activity by using our developed full-length
HCV RNA replication reporter system (OR6 assay system) [9].
This system enabled the prompt and precise evaluation of HCV
RNA replication levels (Fig. 1A). OSM exhibited marked anti-
HCV activity at a low concentration (50% effective concentration
(EC50): 0.71 ng/ml) (Fig. 1B) without cytotoxicity (Fig. 1C). OSM’s
anti-HCV activity was maintained at least until 96 h after a single
administration of the reagent (Fig. 1D). These results indicate
that OSM possesses anti-HCV activity at a concentration thatanization of the genome-length HCV RNA replicating in OR6 cells. The position of an
with OSM for 72 h and subjected to RL assay. Relative luciferase unit (RLU) was
treated with OSM for 72 h and subjected to a cell viability assay with trypan blue
subjected to RL assay.
Fig. 2. The activities of LIF, IL-6 and IL-31 on HCV RNA replication. OR6 cells were treated with LIF (A), IL-6 (B) and IL-31 (C) for 72 h and subjected to RL assay. (D) RNAs from
hepatocytes (HuH-7, Li23 and PH5CH) were subjected to RT-PCR with speciﬁc primer pairs to gp130, OSMR, LIFR, IL6R, IL31RA and GAPDH.
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cytokine.3.2. Anti-HCV activity of OSM is a unique feature in the IL-6 family
OSM belongs to the IL-6 family, whose members share the com-
mon gp130 molecule in each receptor [5]. Therefore, we next
examined the activities of other representative IL-6 family mem-
bers (LIF, IL-6) using the OR6 assay system. As shown in Fig. 2A,
LIF had no effect on HCV RNA replication. IL-6 exhibited only a
weak anti-HCV activity at the concentration of 10 ng/ml (approxi-
mately 20% inhibition) (Fig. 2B).
The OSM receptor consists of gp130 and OSMR [5]. IL31RA is an-
other partner of OSMR and that the heterodimer of these molecules
forms a receptor of IL-31 [6]. Therefore, we tried to determine
whether or not IL-31 possesses anti-HCV activity in OR6 cells.
The result revealed that IL-31 exhibited no anti-HCV activity. Next
we examined the expression levels of the receptors in HuH-7, Li23
(a human hepatoma cell line) and PH5CH (an immortalized pri-
mary human hepatocyte line). All of these cell lines expressed
gp130, OSMR, LIFR and IL6R but not IL31RA (Fig. 2D). The lack of
1L31RA expression resulted in IL-31 possessing no anti-HCV activ-
ity. These results suggest that OSM’s anti-HCV activity seems to be
a unique feature among IL-6 family members.3.3. OSM synergistically enhanced anti-HCV activity of IFN-a
As HCV RNA contains three exogenous genes (RL, Neo and
encephalomyocarditis virus (EMCV)-internal ribosomal entry site
(IRES)) (Fig. 1A), we tried to determine whether OSM inhibits
authentic HCV RNA replication in order to rule out the possibility
that OSM’s anti-HCV activity is not due to the inhibition of these
exogenous genes. OSM inhibited core and NS5A expression in a
dose-dependent manner (Fig. 3A, lanes 1–3). We next examined
OSM’s anti-HCV activity in combination with IFN-a using authenticHCV-O/RLGE RNA-replicating cells. OSM (1 and 10 ng/ml) drasti-
cally inhibited core and NS5A expression in combination with
IFN-a (2.5, 5, and 10 IU/ml) (Fig. 3A, lanes 4–12).
OSM exhibited anti-HCV activity even at low concentrations,
such as 62 pg/ml, and enhanced the anti-HCV activity of IFN-a
(Fig. 3B). We also examined anti-HCV activity of CsA (0, 0.25, 0.5,
and 1.0 lg/ml) alone or in combination with OSM (10 ng/ml) (Sup-
plementary Fig. 1). OSM enhanced CsA’s anti-HCV activity. Anti-
HCV activity of OSM at 10 ng/ml was almost equal to that of CsA
at 0.5 lg/ml. Then, we performed isobole plot analysis for EC50 of
OSM and IFN-a. In Fig. 3C, dotted line means that the interaction
of two reagents is evaluated as additive effect (or zero interaction).
Points below this line correspond to synergistic interaction (or po-
sitive interaction) and points above this line indicate antagonism
(or negative interaction) [16]. Therefore, isobole plot analysis of
EC70 for OSM and IFN-a revealed that the combination of OSM
and IFN-a exhibited striking synergistic inhibition of HCV RNA rep-
lication (Fig. 3C). Then we investigated whether or not OSM en-
hanced the IFN signaling pathway, since OSM activates STATs
[17]. A kinetic study regarding the phosphorylation of STAT1 and
STAT3 revealed that STAT1 (Y701) was markedly phosphorylated
in the early phase within 60 min but that the phosphorylation level
was reduced at 120 min (Fig. 3D). On the other hand, the phos-
phorylation of STAT1 by IFN-a remained consistent until 120 min
after treatment (Fig. 3D). The phosphorylation kinetics of STAT3
(Y705) by OSM were consistent until 120 min (Fig. 3D). These re-
sults suggest that early-phase activation of STAT1 by OSM may
trigger the synergistic activity in HCV RNA replication in combina-
tion with IFN-a.
3.4. OSM enhanced anti-HCV activity of IFN-a at even the low effective
concentration by itself
As OSM exhibited marked synergistic anti-HCV activity with
IFN-a, we tried to determine whether a low concentration of
OSM could synergistically enhance the anti-HCV activity of IFN-
Fig. 3. Anti-HCV activity of OSM in combination with IFN-a. (A) HCV-O/RLGE-replicating OR6c cells were treated with OSM in combination with IFN-a for 96 h and subjected
to Western blot analysis using anti-core, anti-NS5A and anti-b-actin antibodies. (B) OR6 cells were treated with OSM in combination with IFN-a for 72 h and subjected to RL
assay. (C) Isobole plot analysis (EC70) for OSM and IFN-a in OR6 cells after treatment for 72 h. (D) OR6 cells were treated with OSM and IFN-a for 30, 60 and 120 min and
subjected to Western blot analysis using anti-STAT1, anti-phospho-STAT1 (Y701), anti-STAT3, anti-phospho-STAT3 (Y705) and anti-b-actin antibodies.
M. Ikeda et al. / FEBS Letters 583 (2009) 1434–1438 1437a. For this purpose, we treated OR6 cells with OSM at 25 pg/ml or
50 pg/ml in combination with IFN-a (0, 1, 2, 4, and 8 IU/ml). OSM
alone at 25 pg/ml or 50 pg/ml exhibited only 20% inhibitory activ-Fig. 4. OR6 cells were treated with OSM and IFN-a for 72 h and subjected to RL assay (A).
IFN-a were assigned as 100% (B).ity (Fig. 4A). However, OSM at these concentrations enhanced the
anti-HCV activity of IFN-a up to 60% inhibition, when IFN-a at
8 IU/ml was treated with OSM at 25 pg/ml (Fig. 4B). These resultsRelative RL activity was adjusted when the RL activities of the cells treated with only
1438 M. Ikeda et al. / FEBS Letters 583 (2009) 1434–1438indicate that OSM is not only an anti-HCV reagent by itself but also
a strong adjuvant for IFN-a’s anti-HCV activity.
4. Discussion
In the present study, we found that OSM possesses anti-HCV
activity, which constitutes a new function of this multi-func-
tional cytokine. OSM is involved in liver regeneration and differ-
entiation [7,8]. In the liver, OSM was produced by Kupffer cells
[18], and the OSM signal was transmitted via its receptor, which
consisted of gp130 and OMSR [5]. The IL-6 family members share
gp130 in their receptors; it forms the heterodimer with a unique
partner; for example IL6R in IL-6 and LIFR in LIF [2]. We tested
the activity of LIF and IL-6 on HCV RNA replication. However,
LIF did not exhibit anti-HCV activity, and IL-6 showed only weak
anti-HCV activity compared to the OSM. These results suggest
that OSM’s anti-HCV activity is achieved via OSMR or the
combination of gp130 and OSMR rather than via gp130. Recently,
it was reported that IL31RA was another partner of OSMR in the
IL-31 receptor [6]. If IL-31 could exhibit anti-HCV activity, OSMR
seems to be signiﬁcant in the signal transduction of anti-HCV
activity. However, hepatocytes didn’t seem to be a natural
target of IL-31, because hepatocytes didn’t express IL31RA.
Further study is needed to clarify OSMR’s role in anti-HCV
activity.
Isobole plot analysis revealed that OSM exhibited a striking
synergistic effect in the anti-HCV activity of IFN-a [19]. This syn-
ergistic activity of OSM may be caused by early strong activation
of STAT1 by OSM. Furthermore, OSM enhanced the activity of 20–
50 oligoadenylate synthetase promoter in combination with IFN-a
(data not shown). These results suggest that STAT1 may be the
key player in the synergy between OSM and IFN-a.
In this study, we found OSM’s synergistic activity in the anti-
HCV activity of IFN-a, when OSM was used at a low concentra-
tion (25 pg/ml) with only 20% inhibitory activity against HCV
RNA replication. Surprisingly, OSM at 25 pg/ml enhanced the
anti-HCV activity of IFN-a by up to 60%. RBV is the only adjuvant
to the current PEG-IFN-a therapy for patients with CH C, and the
combination therapy of PEG-IFN-a/RBV achieved only
approximately 55% of the SVR rate. Therefore, OSM will become
a strong partner to the current IFN therapy. As OSM strongly af-
fected the anti-HCV activity of IFN-a, the serum concentration of
OSM will affect the SVR in IFN therapy. The future study regard-
ing the relationship between the serum concentration of OSM
and SVR may provide a clue toward understanding the
resistance to IFN therapy, and the development of OSM as a clin-
ical reagent will serve as a breakthrough in therapy for patients
with CH C.
In conclusion, we found OSM’s anti-HCV activity a newly iden-
tiﬁed function of this multifunctional cytokine. The highlight of
this study is that OSM exhibited a synergistic effect on the anti-
HCV activity of IFN-a even at a low concentration with weak
anti-HCV activity by itself.
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